5-HT3 Antagonists (Antiemetics) and Cardiac Safety

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

266 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-06-30

Study Completion Date

2020-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

5-HT3 antagonists (ondansetron) are highly effective medications for the treatment of nausea and vomiting. However, these medications also associated with potentially severe and life-threatening cardiac adverse drug reactions (ADRs), particularly QT prolongation. Data regarding the cardiac safety and inter-individual variability in cardiac effects of ondansetron when used in vulnerable populations such as children and pregnant women are very limited. The results of this study will enable better-informed therapeutic decision-making regarding the use of ondansetron in children and pregnant women, with the overall goal to improve the safety of these commonly used antiemetic medications. Furthermore, predictive pharmacogenetic markers of severe 5-HT3 antagonist toxicity could be used to identify patients at risk of cardiac toxicity before the drug is administered.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects

NCT01449188

Nausea and Vomiting, Chemotherapy-Induced

COMPLETED PHASE1

The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats

NCT00624208

Myocardial Repolarization

COMPLETED NA

The Effects of Ondansetron on Brain Function

NCT02460341

Brain Function Healthy Adults

COMPLETED PHASE1

Effects of Ondansetron Dose and Timing on Post-operative Nausea and Vomiting

NCT03297021

Post-operative Nausea and Vomiting

COMPLETED PHASE4

Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department

NCT00590317

Nausea and Vomiting

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The specific objectives are to:

1. Determine and compare the cardiac safety profile of ondansetron in children, when used for prevention and management of post-operative nausea and vomiting and chemotherapy induced nausea and vomiting. Identify clinical factors including pre-existing cardiac conditions or physiological conditions that predispose to ventricular arrhythmias, concomitant cardiotoxic chemotherapy or concomitant volatile anaesthetic agents and investigate their impact on cardiac adverse effects of ondansetron.
2. Determine and compare the cardiac safety profile of ondansetron when used in pregnant women or women of a reproductive age for the treatment of hyperemesis gravidarum or post-operative nausea and vomiting. Identify clinical factors including pre-existing cardiac conditions or physiological conditions, which predispose to ventricular arrhythmias that may support implementation of risk mitigation actions.
3. Identify genetic variants associated with 5-HT3 antagonist-induced prolongation of QT interval.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adverse Reaction to Other Drugs and Medicines

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pediatric patients

Children \<6 months to 18 years of age receiving ondansetron for management of:

1. Post-operative nausea and vomiting
2. Chemotherapy-induced nausea and vomiting

Ondansetron

Intervention Type DRUG

All patients will be receiving treatment with ondansetron as part of standard care.

Female patients

Pregnant patients or women of a reproductive age (18-45 years) receiving ondansetron for management of:

1. Hyperemesis gravidarum
2. Post-operative nausea and vomiting

Ondansetron

Intervention Type DRUG

All patients will be receiving treatment with ondansetron as part of standard care.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ondansetron

All patients will be receiving treatment with ondansetron as part of standard care.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Zofran

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Children 6 months - 18 years of age who are being treated with ondansetron for prevention and management of post-operative nausea and vomiting and chemotherapy-induced nausea and vomiting.
2. Pregnant women and women of a reproductive age (18-45 years of age) who are being treated with ondansetron for hyperemesis gravidarum or postoperative nausea and vomiting.